174 related articles for article (PubMed ID: 10759916)
1. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers.
Sheftell F; Rapoport A; Weeks R; Walker B; Gammerman I; Baskin S
Headache; 2000 Feb; 40(2):158-63. PubMed ID: 10759916
[TBL] [Abstract][Full Text] [Related]
2. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
Brandes JL; Visser WH; Farmer MV; Schuhl AL; Malbecq W; Vrijens F; Lines CR; Reines SA;
Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
[TBL] [Abstract][Full Text] [Related]
3. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
[TBL] [Abstract][Full Text] [Related]
4. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A
Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723
[TBL] [Abstract][Full Text] [Related]
5. The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
Hoxha M; Rovati GE; Cavanillas AB
Eur J Clin Pharmacol; 2017 Jul; 73(7):799-809. PubMed ID: 28374082
[TBL] [Abstract][Full Text] [Related]
6. [The role of leukotrienes in inflammation and leukotriene inhibitors].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
[TBL] [Abstract][Full Text] [Related]
7. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.
Reiss TF; Altman LC; Chervinsky P; Bewtra A; Stricker WE; Noonan GP; Kundu S; Zhang J
J Allergy Clin Immunol; 1996 Sep; 98(3):528-34. PubMed ID: 8828530
[TBL] [Abstract][Full Text] [Related]
8. Asthma plus migraine in childhood and adolescence: prophylactic benefits with leukotriene receptor antagonist.
de Souza Carvalho D; Fragoso YD; Coelho FM; Pereira MM
Headache; 2002; 42(10):1044-7. PubMed ID: 12453038
[No Abstract] [Full Text] [Related]
9. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma.
Reicin A; White R; Weinstein SF; Finn AF; Nguyen H; Peszek I; Geissler L; Seidenberg BC
Arch Intern Med; 2000 Sep; 160(16):2481-8. PubMed ID: 10979060
[TBL] [Abstract][Full Text] [Related]
10. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
Reiss TF; Chervinsky P; Dockhorn RJ; Shingo S; Seidenberg B; Edwards TB
Arch Intern Med; 1998 Jun; 158(11):1213-20. PubMed ID: 9625400
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis.
Schäper C; Noga O; Koch B; Ewert R; Felix SB; Gläser S; Kunkel G; Gustavus B
J Investig Allergol Clin Immunol; 2011; 21(1):51-8. PubMed ID: 21370724
[TBL] [Abstract][Full Text] [Related]
12. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis.
Yanase DJ; David-Bajar K
J Am Acad Dermatol; 2001 Jan; 44(1):89-93. PubMed ID: 11148482
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
Angelova-Fischer I; Tsankov N
Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):115-9. PubMed ID: 16200338
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma.
Stelmach I; Jerzynska J; Kuna P
J Allergy Clin Immunol; 2002 Feb; 109(2):257-63. PubMed ID: 11842294
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness to montelukast is associated with bronchial hyperresponsiveness and total immunoglobulin E but not polymorphisms in the leukotriene C4 synthase and cysteinyl leukotriene receptor 1 genes in Korean children with exercise-induced asthma (EIA).
Lee SY; Kim HB; Kim JH; Kim BS; Kang MJ; Jang SO; Seo HJ; Hong SJ
Clin Exp Allergy; 2007 Oct; 37(10):1487-93. PubMed ID: 17883728
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group.
Altman LC; Munk Z; Seltzer J; Noonan N; Shingo S; Zhang J; Reiss TF
J Allergy Clin Immunol; 1998 Jul; 102(1):50-6. PubMed ID: 9679847
[TBL] [Abstract][Full Text] [Related]
17. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis.
Bouchelouche K; Nordling J; Hald T; Bouchelouche P
J Urol; 2001 Nov; 166(5):1734-7. PubMed ID: 11586212
[TBL] [Abstract][Full Text] [Related]
18. Leukotriene D4 inhalation challenge for predicting short-term efficacy of montelukast: a pilot study.
Guan WJ; Shi X; Zheng JP; Gao Y; Jiang CY; Xie YQ; Liu QX; Zhu Z; Guo E; An JY; Yu XX; Liu WT; Zhong NS
Clin Respir J; 2015 Jan; 9(1):111-20. PubMed ID: 24506412
[TBL] [Abstract][Full Text] [Related]
19. Montelukast in the treatment of allergic rhinitis: an evidence-based review.
Nayak A; Langdon RB
Drugs; 2007; 67(6):887-901. PubMed ID: 17428106
[TBL] [Abstract][Full Text] [Related]
20. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma.
Lambiase A; Bonini S; Rasi G; Coassin M; Bruscolini A; Bonini S
Arch Ophthalmol; 2003 May; 121(5):615-20. PubMed ID: 12742837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
